Skip to main content
. 2021 Aug 3;13(1):54–64. doi: 10.1111/jdi.13624

Figure 2.

Figure 2

Effects of canagliflozin on cardiovascular and mortality outcomes in participants of East and South‐East Asian and non‐East and South‐East Asian countries in Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE). ACM, all‐cause mortality; Cana, canagliflozin; CI, confidence interval; CV death, cardiovascular death; EA, East and South‐East Asia; HHF, hospitalization for heart failure; MI, myocardial infarction; non‐EA, non‐East and South‐East Asia.